Mankind Pharma posts Q4 FY25 consolidated PAT Rs. 425.11 Cr
The company has posted net profit of Rs. 1,986.43 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 1,986.43 crores for the Financial Year ended March 31, 2025
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
For over 13 years, Star Imaging has pioneered the introduction of next-generation radiology technologies in Pune
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
Global Health has posted net profit of Rs. 481.43 crores for the Financial Year ended March 31, 2025
Indraprastha Medical Corporation has reported total income of Rs. 340.10 crores during the period ended March 31, 2025
The company has posted net profit of Rs. 485.62 crores for the Financial Year ended March 31, 2025
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Subscribe To Our Newsletter & Stay Updated